16 results
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
on pharmacologic treatment. If approved, the prospect that paltusotine can offer an innovative, once-daily oral alternative represents a significant step
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
11 Sep 23
Regulation FD Disclosure
6:05am
of carcinoid syndrome, as well as advance the rest of our innovative pipeline of internally discovered investigational compounds for people who live with other
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
14 Nov 22
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:15am
. The Innovation Passport enables Crinetics to access the Innovative Licensing and Access Pathway (ILAP). The ILAP aims to reduce the time to market
8-K
EX-99.1
csh4on9lgmwvy8
30 Mar 22
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
4:05pm
8-K
EX-99.1
3l4u91
10 Aug 21
Crinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results
4:05pm
8-K
EX-99.1
cv6 xpmpcwqvim1
3 Sep 20
Crinetics Pharmaceuticals Appoints Rare Disease Executive, Camille L. Bedrosian, M.D., to Board of Directors
7:35am
10-K
7vboz32mvdikn lvk
13 Mar 19
Annual report
4:06pm
424B4
opfklfs607u6r xu
18 Jul 18
Prospectus supplement with pricing info
5:27pm
S-1/A
khy18qa 7gk
9 Jul 18
IPO registration (amended)
6:10am
S-1
4qeey
22 Jun 18
IPO registration
4:07pm
DRS/A
mgf0c7p4ltzuh rgb
11 Jun 18
Draft registration statement (amended)
12:00am
DRS
r1uxjs97wc
3 May 18
Draft registration statement
12:00am
- Prev
- 1
- Next